114 related articles for article (PubMed ID: 12137598)
1. [The role of Fas/Fas ligand in tumorgenesis, immune escape, and counterattack in colonic cancer].
Zhu Q; Deng C
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):378-80. PubMed ID: 12137598
[TBL] [Abstract][Full Text] [Related]
2. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
3. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
5. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
[TBL] [Abstract][Full Text] [Related]
6. [The role of Fas/FasL system in the regulation of tumor-immune system interactions in papillary thyroid carcinoma in children and adolescents].
Portianko AS; Cherstvoĭ ED
Arkh Patol; 2003; 65(4):18-21. PubMed ID: 14518188
[TBL] [Abstract][Full Text] [Related]
7. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
[TBL] [Abstract][Full Text] [Related]
8. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.
Okada K; Komuta K; Hashimoto S; Matsuzaki S; Kanematsu T; Koji T
Clin Cancer Res; 2000 Sep; 6(9):3560-4. PubMed ID: 10999744
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
10. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
12. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells.
Asanuma K; Tsuji N; Endoh T; Yagihashi A; Watanabe N
J Immunol; 2004 Mar; 172(6):3922-9. PubMed ID: 15004200
[TBL] [Abstract][Full Text] [Related]
13. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
14. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
[TBL] [Abstract][Full Text] [Related]
15. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
Xu LN; Zou SQ; Wang JM
World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
[TBL] [Abstract][Full Text] [Related]
18. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
Zhang W; Ding EX; Wang Q; Zhu DQ; He J; Li YL; Wang YH
World J Gastroenterol; 2005 Jun; 11(23):3632-5. PubMed ID: 15962391
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]